These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24078223)

  • 1. Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment.
    Ramírez de Arellano A; Coca A; de la Figuera M; Rubio-Terrés C; Rubio-Rodríguez D; Gracia A; Boldeanu A; Puig-Gilberte J; Salas E
    Appl Health Econ Health Policy; 2013 Oct; 11(5):531-42. PubMed ID: 24078223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.
    Rubio-Terrés C; Soria JM; Morange PE; Souto JC; Suchon P; Mateo J; Saut N; Rubio-Rodríguez D; Sala J; Gracia A; Pich S; Salas E
    Appl Health Econ Health Policy; 2015 Apr; 13(2):233-42. PubMed ID: 25652150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain.
    Latour-Pérez J; Navarro-Ruiz A; Ridao-López M; Cervera-Montes M
    Value Health; 2004; 7(1):52-60. PubMed ID: 14720130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the value of a genetic risk score in improving the estimation of coronary risk.
    Lluis-Ganella C; Subirana I; Lucas G; Tomás M; Muñoz D; Sentí M; Salas E; Sala J; Ramos R; Ordovas JM; Marrugat J; Elosua R
    Atherosclerosis; 2012 Jun; 222(2):456-63. PubMed ID: 22521901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
    Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
    Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
    Walter E; Dellago H; Grillari J; Dimai HP; Hackl M
    Bone; 2018 Mar; 108():44-54. PubMed ID: 29269173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.
    Marrugat J; Subirana I; Comín E; Cabezas C; Vila J; Elosua R; Nam BH; Ramos R; Sala J; Solanas P; Cordón F; Gené-Badia J; D'Agostino RB;
    J Epidemiol Community Health; 2007 Jan; 61(1):40-7. PubMed ID: 17183014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
    De Smedt D; Kotseva K; De Bacquer D; Wood D; De Backer G; Dallongeville J; Seppo L; Pajak A; Reiner Z; Vanuzzo D; Georgiev B; Gotcheva N; Annemans L
    Eur Heart J; 2012 Nov; 33(22):2865-72. PubMed ID: 22843446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study.
    Buitrago F; Calvo-Hueros JI; Cañón-Barroso L; Pozuelos-Estrada G; Molina-Martínez L; Espigares-Arroyo M; Galán-González JA; Lillo-Bravo FJ
    Ann Fam Med; 2011; 9(5):431-8. PubMed ID: 21911762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction.
    Gerber A; Evers T; Haverkamp H; Lauterbach KW
    Eur J Health Econ; 2006 Dec; 7(4):247-54. PubMed ID: 16821072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
    Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
    Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
    Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
    J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.